Myriad Genetics
Stock Forecast, Prediction & Price Target
Myriad Genetics (MYGN) stock Price Target by analysts
$27.5
Potential upside: 392.91%
Myriad Genetics price prediction
What is Myriad Genetics stock analysts` prediction?
Myriad Genetics stock forecast: Based on 2 Wall Street analysts` predicted price targets for Myriad Genetics in the last 3 months, the avarage price target is $27.5, with a high forecast of $NaN. The average price target represents a 392.91% change from the last price of $5.58.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
Myriad Genetics stock Price Target by analysts
Full breakdown of analysts given Myriad Genetics price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Puneet Souda Leerink Partners | 0% 0/1 | 10 months ago | $21 276.41% upside | $15.15 | StreetInsider | Previous targets (0) |
Sung Ji Nam Scotiabank | 0% 0/2 | 12 months ago | $34 509.42% upside | $24.67 | StreetInsider | Previous targets (1) |
Tejas Savant Morgan Stanley | 0% 0/1 | about 1 year ago | $32 473.57% upside | $28.47 | TheFly | Previous targets (0) |
Brandon Couillard Wells Fargo | 0% 0/1 | about 1 year ago | $35 527.35% upside | $27.5 | TheFly | Previous targets (0) |
Subbu Nambi Guggenheim | 0% 0/1 | about 1 year ago | $29 419.80% upside | $25.96 | TheFly | Previous targets (0) |
Sung Ji Nam Scotiabank | 0% 0/2 | over 1 year ago | $29 419.80% upside | $24.62 | TheFly | Previous targets (1) |
Jon Peterson Piper Sandler | 0% 0/1 | over 1 year ago | $28 401.88% upside | $25.07 | StreetInsider | Previous targets (0) |
David Westenberg Piper Sandler | 100% 1/1 | almost 2 years ago | $23 312.26% upside | $20.49 | Benzinga | Previous targets (0) |
Mason Carrico Stephens | 100% 1/1 | almost 3 years ago | $22 294.33% upside | $20.82 | TheFly | Previous targets (0) |
Unknown Goldman Sachs | N/A | over 3 years ago | $23 312.26% upside | $23.03 | Benzinga | N/A |
Myriad Genetics Financial Estimates
Myriad Genetics Revenue Estimates
Myriad Genetics EBITDA Estimates
Myriad Genetics Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $690.6M N/A | $678.4M -1.76% | $753.2M 11.02% | Avg: $898.75M Low: $886.27M High: $908.71M avg. 19.32% | Avg: $965.49M Low: $951.34M High: $975.77M avg. 7.42% | Avg: $984.63M Low: $970.19M High: $995.10M avg. 1.98% | Avg: $993.78M Low: $979.21M High: $1.00B avg. 0.93% |
Net Income
% change YoY
| $-27.2M N/A | $-112M -311.76% | $-263.3M -135.08% | Avg: $-72.37M Low: $-101.55M High: $-15.31M avg. 72.51% | Avg: $-29.53M Low: $-63.67M High: $1.61M avg. 59.19% | Avg: $30.56M Low: $29.98M High: $30.99M avg. 203.49% | Avg: $25.36M Low: $24.88M High: $25.71M avg. -17.02% |
EBITDA
% change YoY
| $14.1M N/A | $-67.8M -580.85% | $-186.1M -174.48% | Avg: $-17.74M Low: $-17.94M High: $-17.50M avg. 90.46% | Avg: $-19.06M Low: $-19.26M High: $-18.78M avg. -7.42% | Avg: $-19.44M Low: $-19.65M High: $-19.15M avg. -1.98% | Avg: $-19.62M Low: $-19.83M High: $-19.33M avg. -0.93% |
EPS
% change YoY
| -$0.35 N/A | -$1.39 -297.14% | -$3.18 -128.77% | Avg: -$0.69 Low: -$1.26 High: -$0.19 avg. 78.35% | Avg: -$0.24 Low: -$0.79 High: $0.02 avg. 65.13% | Avg: $0.38 Low: $0.37 High: $0.38 avg. 258.03% | Avg: $0.31 Low: $0.31 High: $0.32 avg. -17.02% |
Operating Expenses
% change YoY
| $681.7M N/A | $600.1M -11.97% | $774.4M 29.04% | Avg: $688.72M Low: $679.15M High: $696.34M avg. -11.06% | Avg: $739.86M Low: $729.01M High: $747.73M avg. 7.42% | Avg: $754.52M Low: $743.45M High: $762.55M avg. 1.98% | Avg: $761.54M Low: $750.37M High: $769.64M avg. 0.93% |
FAQ
What is Myriad Genetics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 79.54% in 2025-2028.
We have gathered data from 8 analysts. Their low estimate is -101.55M, average is -72.37M and high is -15.31M.
What is Myriad Genetics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 7.41% in 2025-2028.
We have gathered data from 10 analysts. Their low revenue estimate is $886.27M, average is $898.75M and high is $908.71M.
What is Myriad Genetics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 96.12% in 2025-2028.
We have gathered data from 8 analysts. Their low earnings per share estimate is -$1.26, average is -$0.69 and high is $-0.19.
What is the best performing analyst?
In the last twelve months 2 analysts have been covering Myriad Genetics stock. The most successful analyst is Puneet Souda.